PCSK 9 Inhibitor Added to High-Intensity Statin Therapy to Prevent Cardiovascular Events in Patients With Acute Coronary Syndrome After Percutaneous Coronary Intervention: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study
Latest Information Update: 15 Apr 2024
At a glance
- Drugs Evolocumab (Primary) ; Rosuvastatin
- Indications Acute coronary syndromes
- Focus Therapeutic Use
- Acronyms ETACS; SHAWN
- 14 May 2023 Status changed from not yet recruiting to recruiting.
- 19 Jul 2022 New trial record